文献速递贫血与红细胞疾病白血病淋巴瘤

诊断时及移植前维生素D水平对血液肿瘤预后影响的Meta分析

Impact of vitamin D level at diagnosis and transplantation on the prognosis of hematological malignancy: a meta-analysis.
PubMed 文献 · Blood Adv · 2022-01-01

结果显示,较低的维生素D水平与髓系和淋系恶性肿瘤较差的OS和PFS显著相关,且移植前低维生素D水平与自体及异体HSCT较差的OS相关。

要点

  • 低维生素D水平与髓系肿瘤较差OS(HR 1.39)和PFS(HR 2.03)显著相关。
  • 低维生素D水平与淋系肿瘤较差OS(HR 2.07)和PFS(HR 1.91)显著相关。
  • 移植前低维生素D水平与自体HSCT(HR 1.65)和异体HSCT(HR 1.50)较差OS相关。

核心结论

  • 较低的维生素D水平与髓系及淋系恶性肿瘤较差的OS和PFS显著相关。
  • 移植前较低的维生素D水平与自体及异体HSCT较差的OS显著相关。

研究设计与样本

  • 采用固定效应模型和随机效应模型分析主要结局OS和PFS。

主要发现

  • 髓系恶性肿瘤中,低维生素D水平与较差OS相关(HR 1.39;95%CI 1.06-1.82),与较差PFS相关(HR 2.03;95%CI 1.23-3.32)。
  • 淋系恶性肿瘤中,低维生素D水平与较差OS相关(HR 2.07;95%CI 1.79-2.40),与较差PFS相关(HR 1.91;95%CI 1.61-2.25)。
  • 低维生素D水平与多个淋巴瘤亚型各自的结局相关。
  • 移植前低维生素D水平与自体HSCT较差OS相关(HR 1.65;95%CI 1.04-2.61),与异体HSCT较差OS相关(HR 1.50;95%CI 1.03-2.18)。

临床怎么用

  • 对血液肿瘤患者,诊断时及移植前评估维生素D水平可能有助于预后分层。
  • 低维生素D水平提示髓系、淋系肿瘤及HSCT患者预后较差,需关注维生素D状态。

局限性

  • 评估的研究数量相对较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vitamin D deficiency impairs prognosis in many types of cancer; however, its significance in each subtype of hematological malignancies is unclear. In addition, data on the association between pretransplant vitamin D levels and outcomes of hematopoietic stem cell transplantation (HSCT) are inconsistent. This systematic review and meta-analysis aimed to elucidate the impact of vitamin D levels at diagnosis or pre-HSCT on the prognosis of hematological malignancies. Thirty articles and abstracts were extracted from PubMed, Embase, and Cochrane Library databases and conference proceedings. Fixed and random effect models were used to analyze primary outcomes: overall survival (OS) and progression-free survival (PFS). Lower vitamin D level was significantly associated with poorer OS and PFS in myeloid malignancies (hazard ratio [HR], 1.39; 95% confidence interval [CI], 1.06-1.82 and HR, 2.03; 95% CI, 1.23-3.32, respectively) and lymphoid malignancies (HR, 2.07; 95% CI, 1.79-2.40 and HR, 1.91; 95% CI, 1.61-2.25, respectively), as well as outcomes for several lymphoma subtypes individually. Furthermore, a lower pretransplant vitamin D level was associated with poorer OS in autologous and allogeneic HSCT (HR, 1.65; 95% CI, 1.04-2.61 and HR, 1.50; 95% CI, 1.03-2.18, respectively). Despite the relatively small number of studies evaluated, these data suggest the importance of vitamin D status in outcomes of hematological malignancies (PROSPERO registration number: CRD42020205821).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ito Y, Honda A, Kurokawa M, et al. Impact of vitamin D level at diagnosis and transplantation on the prognosis of hematological malignancy: a meta-analysis. Blood Adv. 2022. PMID: 34496015. doi:10.1182/bloodadvances.2021004958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。